It is a broadly described annual report of The IBN SINA Pharmaceutical Industry Limited in the year of 2014. The IPI had made a significant contribution in 2014 towards the National Exchequer by paying Tk. 485,883,681 as Income Tax and VAT’ this is equivalent to 1 8. l4% of the sales n the year under review. During the year 21.29% Sales growth was achieved compared to the growth rate of Lg2% in the preceding year. In the year 2014 overall sales achievement stood at Taka. 2,678.91 million, which was Taka. 2,208.72 million In the last year. The company’s net profit after tax Taka.127,278,420. In the year 2014 IPI shares were traded on both stock exchanges at min mum of Tk. 90.00 to the maximum of Tk. 133.40 as against the face value of Tk.10.00.
In 2014, Company’s reserve and surplus rose to Tk. 259,286,963 which was Tk. 200,048,543 in the previous year. After evaluating the Financial Statements for the year 2014 of the Company, the Board of Directors proposed a stock dividend of 05% and the cash dividend of 30% per share of Tk.10 each.
More Annual Report of The IBN SINA Pharmaceutical Industry Limited:
- Annual Report 2010 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2011 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2012 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2013 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2014 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2017 of The IBN SINA Pharmaceutical Industry Limited
